CLSA released a research report stating that it has adjusted its valuation based on the latest data. Using a discounted cash flow (DCF) approach, the firm raised its target price for SKB BIO-B (06990) by 52% from HK$328.4 to HK$500.6, while reiterating its "Outperform" rating. The report noted that the company's flagship product generated sales of RMB 310 million, primarily driven by sac-TMT. The indication expansion for second-line non-small cell lung cancer (NSCLC) is expected to further support sales growth in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.